Segocort 6mg Tablet DEFLAZACORT
Introduction to Segocort 6mg Tablet
Segocort 6mg Tablet is a medication primarily used to treat certain inflammatory and autoimmune conditions. It contains the active ingredient Deflazacort, which is a type of corticosteroid. This medication helps in reducing inflammation and suppressing the immune system to provide relief from symptoms.
Composition of Segocort 6mg Tablet
The main component of Segocort 6mg Tablet is Deflazacort. It is formulated to be taken orally and is available in a 6mg dosage strength.
Uses of Segocort 6mg Tablet
- Treatment of Duchenne muscular dystrophy (DMD) in children aged 5 and older.
- Management of various inflammatory and autoimmune conditions.
- Reduction of inflammation and suppression of the immune response.
Side effects of Segocort 6mg Tablet
Common side effects:
- Weight gain
- Increased appetite
- Round face (Cushingoid appearance)
- Upper respiratory infections (common cold)
- Frequent urination
- Nose and throat inflammation
- Excessive hair growth
- Irritability
Serious side effects:
- Allergic reactions such as rash, itching, or swelling
- Severe dizziness
- Trouble breathing
Precautions of Segocort 6mg Tablet
Before taking Segocort 6mg Tablet, inform your doctor if you are allergic to it or any of its ingredients. Use with caution during pregnancy and breastfeeding. Do not stop taking this medication suddenly, as it can lead to steroid withdrawal syndrome, causing symptoms like loss of appetite, nausea, vomiting, tiredness, and headache.
How to Take Segocort 6mg Tablet
- Take the tablet once daily by mouth.
- The recommended dose is about 0.9 mg for each kilogram of body weight.
- It can be taken with or without food, but avoid grapefruit juice.
Conclusion of Segocort 6mg Tablet
Segocort 6mg Tablet is an effective medication for managing certain inflammatory and autoimmune conditions. It is important to follow your doctor's instructions and be aware of potential side effects. Always consult your healthcare provider for personalized advice and guidance.